Sotac Pharmaceuticals Limited (NSE:SOTAC)
India · Delayed Price · Currency is INR 122.50
-0.50 (-0.41%)
At close: Sep 17, 2025
Sotac Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Operating Revenue | 1,048 | 1,038 | 774.83 | 731.52 | 488.43 | 286.04 |
Other Revenue | 1.01 | 1.01 | - | - | - | - |
| 1,049 | 1,039 | 774.83 | 731.52 | 488.43 | 286.04 | |
Revenue Growth (YoY) | 17.35% | 34.13% | 5.92% | 49.77% | 70.76% | - |
Cost of Revenue | 823.1 | 796.12 | 572.69 | 559.77 | 393.92 | 214.27 |
Gross Profit | 225.75 | 243.2 | 202.14 | 171.75 | 94.51 | 71.76 |
Selling, General & Admin | 36.09 | 40.36 | 42.93 | 30.04 | 31.78 | 17.13 |
Other Operating Expenses | 102.48 | 114.63 | 83.31 | 61.93 | 48.19 | 36.01 |
Operating Expenses | 170.56 | 186 | 149.01 | 103.24 | 105.9 | 67.14 |
Operating Income | 55.19 | 57.2 | 53.13 | 68.51 | -11.39 | 4.62 |
Interest Expense | -16.58 | -15.51 | -19.02 | -5.02 | -9.96 | -2.19 |
Interest & Investment Income | 1.82 | 1.82 | 0.46 | 0.48 | 0.74 | 0.42 |
Currency Exchange Gain (Loss) | -0.07 | -0.07 | - | - | - | - |
Other Non Operating Income (Expenses) | 4.59 | -1.81 | -1.11 | 1.33 | 0.04 | 0.25 |
EBT Excluding Unusual Items | 44.94 | 41.63 | 33.47 | 65.31 | -20.57 | 3.11 |
Gain (Loss) on Sale of Investments | - | - | - | -18.36 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.47 |
Other Unusual Items | -2.34 | -2.34 | 5.8 | - | - | - |
Pretax Income | 42.95 | 39.64 | 39.27 | 46.95 | -20.57 | 3.57 |
Income Tax Expense | 1.43 | 3.85 | 16.41 | 18.16 | 3.09 | 2.7 |
Earnings From Continuing Operations | 41.52 | 35.79 | 22.86 | 28.79 | -23.65 | 0.88 |
Minority Interest in Earnings | 3.08 | 7.02 | 5.93 | - | - | - |
Net Income | 44.6 | 42.81 | 28.79 | 28.79 | -23.65 | 0.88 |
Net Income to Common | 44.6 | 42.81 | 28.79 | 28.79 | -23.65 | 0.88 |
Net Income Growth | 81.24% | 48.69% | 0.02% | - | - | - |
Shares Outstanding (Basic) | 11 | 11 | 8 | 8 | 8 | 3 |
Shares Outstanding (Diluted) | 11 | 11 | 8 | 8 | 8 | 3 |
Shares Change (YoY) | - | 36.35% | - | - | 132.16% | - |
EPS (Basic) | 4.04 | 3.90 | 3.58 | 3.58 | -2.94 | 0.25 |
EPS (Diluted) | 4.04 | 3.90 | 3.58 | 3.58 | -2.94 | 0.25 |
EPS Growth | - | 9.04% | 0.02% | - | - | - |
Free Cash Flow | -60.84 | -339.11 | -8.57 | 28.46 | -34.68 | -97.44 |
Free Cash Flow Per Share | -5.51 | -30.89 | -1.06 | 3.54 | -4.31 | -28.10 |
Dividend Per Share | - | - | - | 2.000 | - | - |
Gross Margin | 21.52% | 23.40% | 26.09% | 23.48% | 19.35% | 25.09% |
Operating Margin | 5.26% | 5.50% | 6.86% | 9.37% | -2.33% | 1.62% |
Profit Margin | 4.25% | 4.12% | 3.72% | 3.94% | -4.84% | 0.31% |
Free Cash Flow Margin | -5.80% | -32.63% | -1.11% | 3.89% | -7.10% | -34.07% |
EBITDA | 87.13 | 88.16 | 75.89 | 79.77 | 14.54 | 18.61 |
EBITDA Margin | 8.31% | 8.48% | 9.79% | 10.90% | 2.98% | 6.51% |
D&A For EBITDA | 31.94 | 30.95 | 22.76 | 11.26 | 25.93 | 13.99 |
EBIT | 55.19 | 57.2 | 53.13 | 68.51 | -11.39 | 4.62 |
EBIT Margin | 5.26% | 5.50% | 6.86% | 9.37% | -2.33% | 1.62% |
Effective Tax Rate | 3.33% | 9.70% | 41.78% | 38.68% | - | 75.50% |
Revenue as Reported | 1,059 | 1,043 | 778.33 | 733.7 | 489.5 | 288.26 |
Advertising Expenses | - | 0.05 | 0.3 | 0.02 | - | 0 |
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.